Pico-Tesla Magnetic Therapies, an emerging medical technology company based in Littleton, CO, has commenced a pilot study of its Magneceutical™ Therapy as a treatment for type 2 diabetes, the most common form of the disease.
On 11/19/09, the Company announced positive results in a pilot clinical study which included Prelude skin preparation and the placement of 10 Symphony tCGM biosensors on subjects with Type 1 or Type 2 Diabetes.
The U.S. Preventive Services Task Force recommended this week that women should begin getting routine mammograms at the age of 50 instead of the previously recommended age of 40.
Shares in Spherix shot up by 77 percent after the biotechnology company announced preliminary Phase III results for its Type 2 diabetes drug candidate.
If the past week is any indication, big pharma is showing that it is willing to pay for biotech innovation.
Adeona Pharmaceuticals, a developer of medications for CNS and autoimmune diseases, announced data from a Phase II clinical trial of its rheumatoid arthritis drug candidate.
NicOx announced that NCX 6560, its drug candidate for high cholesterol, met its primary and secondary endpoints in a Phase Ib man-in study.
The Cambridge, Mass.-based company has signed a $75 million deal with Astella Pharmaceuticals to market Ironwood’s IBS drug in Asia.
Avanir, a pharmaceutical company developing treatments for CNS disorders and inflammatory diseases, announced that its multiple sclerosis drug Zenvia met its goal in a six-month clinical trial.
Protox Therapeutics applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on prostate conditions and cancer.
Copyright © 2025 | WordPress Theme by MH Themes